What is the role of beta-blockers in the treatment of Wolff-Parkinson-White (WPW) syndrome?

Updated: Jan 08, 2017
  • Author: Christopher R Ellis, MD, FACC, FHRS; Chief Editor: Mikhael F El-Chami, MD  more...
  • Print
Answer

Beta-blockers are probably the medications most commonly used to treat SVT in the presence of preexcitation. They are moderately effective and have frequent, but rarely life-threatening, adverse effects (except in the presence of reactive airway disease). Their efficacy in reducing the risk of accelerated conduction of AF in WPW patients is unclear. More potent medications (eg, flecainide, propafenone, sotalol, or amiodarone) may have more effect on accessory pathway (AP) conduction or refractoriness than beta-blockers and are preferred by some.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!